I disagree that financing is a smokescreen. New financing terms will give indirect guidance, indicating the future viability of the company both short term and long. If DMRJ increase rates to 20% with a 6 month balloon and free warrants included, this signals something quite different than a 5 year term at 8% with no warrants attached. Likewise, if Implant has other financing options, that they tap on decent terms, it could indicate they have competitive options to DMRJ. Equity swaps or a cash raise via equity markets will impact as well.
A weak balance sheet with an unknown financial pathway is certain to be a SP drag.